John Libbey Eurotext

Clinical course of intoxication with the new anticonvulsant drug perampanel Volume 15, issue 3, September 2013

Klinik für Neurologie, RKU, Ulm, Leitender Oberarzt Neurologische Klinik, Abteilungsleiter Konservative Epileptologie, Krankenhaus Rummelsberg gGmbH, Rummelsberg, Schwarzenbruck, Germany

Perampanel has recently been approved as an anticonvulsant drug for focal epilepsies. Phase III trials have shown good tolerability, although data regarding effects of high doses of perampanel are not available. Here, we describe the first case of a 34-year-old patient with perampanel intoxication and attempted suicide, in which the recommended daily dose of perampanel was exceeded ten-fold. Clinical signs of the intoxication and possible psychotropic effects are described.